The Interplay Between PMOS and MASLD: Pathophysiology and Evidence-Based Nutritional Interventions - PubMed
2 hours ago
- #PMOS
- #MASLD
- #nutritional interventions
- PMOS (Polyendocrine Metabolic Ovarian Syndrome) is the most common endocrine disorder in reproductive-age women, with about 18% prevalence based on Rotterdam criteria, often involving dyslipidemia, insulin resistance, hyperandrogenism, central adiposity, and chronic inflammation.
- Women with PMOS are at higher risk of developing MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), a widespread chronic liver condition affecting around 25% of the global population, as both disorders share overlapping metabolic risk factors.
- A review of nearly 30 studies suggests that an anti-inflammatory diet, omega-3 supplementation, and myo-inositol form an evidence-based initial strategy for managing coexisting PMOS and MASLD, though most evidence comes from studies on either condition separately.
- Current research lacks studies on individuals with both PMOS and MASLD, highlighting the need for long-term randomized controlled trials in diverse populations to strengthen nutritional intervention guidelines.
- Nutritional approaches may evolve from supplementary to primary therapeutic strategies for PMOS and MASLD management as more evidence emerges, addressing the growing global burden of these conditions in women of reproductive age.